Thank you to our speakers, sponsors, and delegates who joined us in Boston! If you are interested in the 2026 event, please get in touch at info@hansonwade.com
Harmonizing Strategic Partnerships & Patient-Centric Biomarker & Drug-Diagnostic Strategies with Regulatory Expectations to Streamline Access to Safer, More Efficacious Precision Therapeutics
Driven by advancements in genomic profiling, omics, and AI technologies, the biomarkers and diagnostics field continues to surge, with Roche and AstraZeneca’s world-first digital pathology CDx approval in April taking the number of approved CDx tests to a record high of 188.
We are now witnessing a need for new, stronger co-development partnerships to validate novel biomarkers, navigate global in vitro diagnostic regulation, and harmonize commercialization; which will in turn accelerate adoption of these drug-diagnostics across diverse therapeutic areas and markets.
World Clinical Biomarkers & Companion Diagnostics Summit returned for its 15th anniversary and united 700+ industry leaders across biopharma, CDx developers, testing labs, regulators, and payers to advance clinical biomarker strategies and accelerate drug-diagnostics to market for improved patient diagnosis, stratification, and monitoring.
Biotechs Attending Included











